Compliance to six weeks supplementation of a nutritional concept constituted as a powder in HIV-1 positive adults not on Highly Active Anti-Retroviral Therapy (HAART): an open-label single-centre pilot study

Danone Research (Netherlands)0 个研究点目标入组 24 人开始时间: 2011年5月19日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Human immunodeficiency virus (HIV)-1 positive adults who have not received HAART in the past year and are not anticipated to start HAART during the study period
•2. Age 18 years and older
•3. Males and non-pregnant, non-lactating females
•4. CD4+ T-cell count 350 cells/µL or higher
•5. Written informed consent

•1. Lactose intolerance (not using a stable dose of lactase) or known allergy for any of the ingredients
•2. Unable to adhere to protocol instructions (including illiterate persons)
•3. Known inflammatory bowel diseases, coeliac disease
•4. Investigators' uncertainty about the willingness or ability of the subject to comply with the protocol requirements [including intravenous (IV) drug users]
•5. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study and during the course of the study

发起方

Danone Research (Netherlands)